I got asked to settle a bar argument. Anastrozole or testosterone, which one do you take. I said neither answer is right because the question is rigged. Then I went and checked the paperwork, because that’s the job.
Here’s the setup. Two drugs get named in the same breath online like they’re competing candidates for the same job opening. They’re not. One replaces a hormone. The other blocks an enzyme. Different case files entirely. Somebody sold men on the idea that this is a fork in the road, and once you buy that story, you’re primed to add a drug you don’t need. That’s where the money and the harm both live, so that’s where I started digging.
First, the disclosure, because it changes how you read everything after it. Both drugs need a prescription. The men’s-health use of both is partly off-label. Most anastrozole men actually get is compounded, not the factory tablet. And the number that should run this whole decision doesn’t come from a forum thread. It comes off a lab panel. Keep that in your pocket. It’s the thread that runs through the rest of this.
The two files
Testosterone’s file is simple. Man is low, testing confirms it, symptoms match, you replace what’s missing. No trick to it. It’s a hormone, he’s short, you top it up.
Anastrozole’s file reads different. It doesn’t put anything into you. It jams a lock, specifically the aromatase enzyme, the one that turns some of your testosterone into estradiol. Block the lock, estrogen drops. That’s the whole trick. It never treated low testosterone and it was never built to. Check the actual approval and there’s only one signature on it: aromatase-driven breast cancer in postmenopausal women [1]. Everything else, every use in a man, is off-label, working a job the paperwork never assigned it. In that off-label world its only real function is knocking estradiol down when a man’s estradiol has actually climbed too high, usually as fallout from testosterone therapy itself.
So look at the relationship again, because this is the part that gets buried. One drug supplies a hormone. The other manages a side effect that sometimes shows up after you supply it. That’s not two suspects for the same crime. That’s a cause and, sometimes, a consequence.
Where the story gets sold wrong
Here’s the pattern I kept finding. Man starts testosterone. Man reads that testosterone raises estrogen. Man decides he now has a decision to make, testosterone versus anastrozole, like it’s a two-horse race. But there was never a race. Testosterone is already doing its job, treating the low testosterone. The only question left standing is a separate one, and it’s not rhetorical: is his estradiol actually too high, and is it causing him grief. That’s a blood draw, not an assumption.
Most of the time, when I traced it back, the honest answer is he didn’t need the second drug at all. A lot of men run a well-dosed testosterone protocol and never touch an aromatase inhibitor in their lives. The American Urological Association’s own guideline treats aromatase inhibitors as a conditional option, mostly for men protecting fertility, resting on low-certainty evidence, not as standard equipment bolted onto every testosterone script [5]. So the guy who thinks he’s choosing between two treatments is usually choosing between testosterone alone, which is the actual medicine, and testosterone plus a drug he never needed, which is testosterone plus a risk he volunteered for.
That’s the reframe that actually protects you. You’re almost never picking between two options. You’re deciding whether to add a second one on top of the first, and until a lab result says otherwise, the answer is no.
The one thing that holds up
I don’t trust round numbers and I don’t trust marketing copy. What holds up is the controlled data, so here it is straight.
Estradiol isn’t the villain in this story. In a man it’s doing work, bone, brain, libido, joints, cholesterol. Push it down too far and you’ll feel it, and there’s a paper trail proving the cost. A one-year randomized, double-blind, placebo-controlled trial in older men with low testosterone found anastrozole lowered estradiol and lowered spine bone mineral density compared to placebo. The investigators’ own conclusion: aromatase inhibition does not improve skeletal health in aging men [3]. A companion trial from the same setup found anastrozole raised testosterone but didn’t improve body composition or strength [2]. Stack those two files side by side and you get a clean picture. Add anastrozole you don’t need, and you’re trading bone density for a payoff that never showed up in the data.
So the man who reflexively “chose” anastrozole as testosterone’s sidekick didn’t optimize a thing. He signed up for a drug whose main documented effect, in his situation, is downside. That’s the exact trap this whole comparison should be warning you off.
When it’s actually a legitimate call
I’m not here to bury a drug that has a real job sometimes. There are cases where anastrozole earns its seat at the table, and pretending otherwise would be its own kind of dishonesty.
The clean case is the heavier man (more body fat, more aromatase enzyme at work) who’s genuinely converting too much testosterone into estradiol, has the lab number to prove it, and has symptoms that line up with it. In that specific man, a low dose of anastrozole can pull estradiol back into range, and it reliably does. In subfertile men with a BMI of 25 or higher, daily anastrozole raised testosterone from roughly 271 to 412 ng/dL and dropped estradiol from about 32 to 16 pg/mL, with fertility markers improving alongside it [7]. That fertility angle is also the narrow lane the guidelines actually carve out for it [5]. And matched head-to-head against clomiphene, anastrozole came out ahead on the testosterone-to-estradiol ratio, even though clomiphene pushed total testosterone higher in that particular trial [6].
Every legitimate case I found has the same fingerprint on it: a measured high estradiol number drove the decision. Not the assumption that testosterone automatically needs a chaperone. Anastrozole belongs in the file when the lab says estrogen is the actual problem. It doesn’t belong there as a default toll charged on every testosterone script.
The call
Skip the versus. Work it in order, because the order is the whole protection.
One: is testosterone actually low, confirmed by testing and symptoms? If yes, that’s the case, and it’s a testosterone conversation, full stop, nothing to do with anastrozole yet. Two: once you’re on testosterone, is estradiol actually measured and actually elevated, with symptoms to match? Not guessed at. Measured. If the number comes back healthy and you feel fine, you’re done, and the correct dose of anastrozole is zero milligrams. Three: only if estradiol is genuinely high and causing trouble does anastrozole even enter the conversation, and even then it’s a low dose tuned to your bloodwork, not a full-strength breast-cancer tablet repurposed for a job it was never built for.
Notice what never happened in that sequence. You never “chose” between two drugs. You treated the low testosterone if it existed, then checked for a specific downstream problem, then acted on it only if the evidence said it was real.
That’s also why supervision isn’t a rubber stamp, it’s the actual mechanism that keeps this sequence honest. A provider that pulls your estradiol and testosterone numbers, sets a sensible dose only when one is warranted, and fills it through a licensed compounding pharmacy is structured to ask these questions in the right order and stop at “zero” when zero is the right answer. FormBlends works this way: clinician evaluation, lab-guided dosing, a licensed compounding pharmacy that can build the low strength most men actually need instead of handing over the 1 mg cancer tablet [1]. The other route, buying an aromatase blocker off a research-chemical site because a forum insisted testosterone requires one, skips every one of those checkpoints and walks straight into the bone-and-libido bill the controlled trials already priced out for you [3].
Where the case closes
Anastrozole versus testosterone was never a real contest, because they were never competing for the same job. Testosterone replaces a hormone you’re actually short on. Anastrozole lowers an estrogen level that’s sometimes, not usually, too high as a result of that replacement. In most files I looked at, the right answer is testosterone alone, with anastrozole held in reserve, not as the other option on the menu, but as a second drug you only add once a blood test says estradiol is genuinely a problem. Add it without that evidence and you’re the one paying, in bone density and libido, for a benefit the controlled data never delivered [2][3]. So drop the choice and run the sequence instead: confirm the low testosterone, treat it, then measure estradiol and act only on what the number says. Most of the time that ends with testosterone doing its job and the anastrozole staying in the bottle. That’s not a compromise. That’s the case closing clean.
What people tend to ask
Does anastrozole stand in for testosterone? No. It doesn’t contain testosterone and doesn’t touch the actual deficiency. It jams the aromatase enzyme to lower estradiol, which manages a possible side effect of testosterone therapy. It’s not a substitute for the hormone itself [1].
Does every man on testosterone need to add an estrogen blocker? No, and most don’t. Plenty of men run a well-dosed protocol without ever needing an aromatase inhibitor. The American Urological Association calls these drugs a conditional option on thin evidence, mostly around fertility, not standard issue with testosterone [5].
What actually justifies adding anastrozole? A measured estradiol number paired with symptoms that track it. Not a hunch. If the lab comes back in healthy range and you feel fine, the right dose is zero [5].
What’s the damage if I take it without needing it? You lose bone and gain nothing. A one-year placebo-controlled trial found anastrozole lowered spine bone mineral density in older men, and a companion study found it raised testosterone without improving body composition or strength [2][3]. Push estradiol too low and the daily cost is the familiar list: flat libido, weak erections, achy joints, low mood.
Why does the dose matter this much for men? The 1 mg tablet was built to shut estrogen production down hard in breast cancer patients, more suppression than a man on testosterone needs or wants. Men who genuinely need it usually do better on a low compounded dose tuned to their own labs, which is exactly why a supervised provider that can dispense lower strengths beats a standard cancer tablet for this job [1].
References
- Anastrozole (Arimidex), FDA Drugs@FDA, Application No. 020541. Confirms approval as an aromatase inhibitor for breast cancer in postmenopausal women, at 1 mg daily; no approved indication in men or for testosterone therapy. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020541
- Burnett-Bowie SM, Roupenian KC, Dere ME, Lee H, Leder BZ. Clin Endocrinol (Oxf). 2009. PMID 18616708. Anastrozole 1 mg daily for one year raised testosterone and lowered estradiol but did not improve body composition or strength. https://pubmed.ncbi.nlm.nih.gov/18616708/
- Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. J Clin Endocrinol Metab. 2009. PMID 19820017. One-year randomized placebo-controlled trial; anastrozole decreased spine bone mineral density versus placebo, concluding aromatase inhibition does not improve skeletal health in aging men.
- American Urological Association. Testosterone Deficiency Guideline (2018, amended 2024). Positions aromatase inhibitors as conditional options primarily for fertility preservation, on low-certainty evidence, not as a routine addition to testosterone therapy.
- Helo S, et al. J Sex Med. 2015;12(8):1761-1769. PMID 26176805. Randomized double-blind trial; anastrozole improved the testosterone-to-estradiol ratio while clomiphene produced higher total testosterone.
- Shah T, Nyirenda T, Shin D. Transl Androl Urol. 2021;10(3). PMID 33850757. In subfertile men with BMI 25 or higher, daily anastrozole raised testosterone from about 271 to 412 ng/dL and lowered estradiol from about 32 to 16 pg/mL, with improved semen parameters.
Written by Kira Bianchi, consumer-health journalist. Reading the studies before believing the pitch. Last reviewed January 2026.
This article is educational and not a substitute for professional medical advice. Check with your doctor first.
